darbepoetin alfa + parenteral iron

**Darbepoetin alfa + parenteral iron** is a combination therapy used primarily to treat anemia, especially in patients with refractory anemia or anemia following autologous hematopoietic cell transplantation. Darbepoetin alfa is a recombinant human erythropoiesis-stimulating agent that acts as an agonist at the erythropoietin receptor, stimulating red blood cell production in the bone marrow. Parenteral iron (typically administered as intravenous iron sucrose) provides essential iron directly into the circulation, facilitating efficient erythropoiesis, particularly in patients where oral iron is inadequate or poorly tolerated. This combination enhances hemoglobin response and erythropoietic efficacy beyond darbepoetin alfa alone and is primarily indicated in chronic kidney disease, cancer-related anemia, inflammatory bowel disease-associated refractory anemia, and post-hematopoietic cell transplantation[1][2][3][5].

Brand names

Aranesp (for darbepoetin alfa)various brands (for parenteral iron, e.g., Venofer for iron sucrose, Ferrlecit for ferric gluconate)

Other names

darbepoetin alpha + intravenous irondarbepoetin alfa + IV irondarbepoetin alfa + iron sucrose